'High-priced Poker Game'

Apr 20, 2012

GlaxoSmithKline has made a $2.6 billion unsolicited offer to take over Human Genome Sciences, reports Brett Chase at Miyanville. But not only has Human Genome rejected Glaxo's offer, it put itself up for sale to the highest bidder, saying Glaxo's offer of $13 a share is too low and doesn't reflect the potential value of the company.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

To See More Clearly

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

Which Fish Is Which?

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

The Suspects, Too

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

This Week in PNAS

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.

Menu